A prospective study of P-IMVP-16/CBDCA: A novel salvage chemotherapy for patients with aggressive non-Hodgkin's lymphoma who had previously received CHOP therapy as first-line chemotherapy

European Journal of Haematology

Volumn 68, Issue 6, 2002, Pages 354-361

  Sawada, Michio ^a   Tsurumi, Hisashi ^a   Yamada, Toshiki ^a   Hara, Takeshi ^a   Fukuno, Kenji ^a   Goto, Hideko ^b   Shimizu, Masahito ^a   Kasahara, Senji ^a   Yoshikawa, Takeshi ^a   Kanemura, Nobuhiro ^a   Oyama, Masami ^b   Takami, Tsuyoshi ^c   Moriwaki, Hisataka ^a  

^a GIFU UNIVERSITY   (Japan)

^b GIFU UNIVERSITY   (Japan)

^c GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Aggressive non Hodgkin's lymphoma; CHOP; IMVP 16; Refractory lymphoma; Relapsed lymphoma; Salvage chemotherapy

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYDAUNORUBICIN; IFOSFAMIDE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; UNCLASSIFIED DRUG; VINCRISTINE SULFATE;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; DIGESTIVE SYSTEM FUNCTION DISORDER; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; INFECTION; KIDNEY DISEASE; LEUKOCYTE COUNT; LIVER DYSFUNCTION; LYMPH NODE METASTASIS; MALE; MULTIVARIATE ANALYSIS; NEUTROPENIA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RISK FACTOR; SALVAGE THERAPY; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT FAILURE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; HUMANS; IFOSFAMIDE; LYMPHOMA, NON-HODGKIN; MALE; METHOTREXATE; METHYLPREDNISOLONE; MIDDLE AGED; NEOPLASM STAGING; PREDNISONE; PROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL RATE; TIME FACTORS; TREATMENT FAILURE; VINCRISTINE;

EID: 18544378882     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0609.2002.01654.x     Document Type: Article

References (22)

1. FISHER RI, GAYNOR ER, DAHLBERG S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328:1002-1006.
2. FISHER RI. Cyclophosphamide, doxorubicin, vincristine, and prednisone versus intensive chemotherapy in non-Hodgkin's lymphoma. Cancer Chemother Pharmacol 1997;40:S42-S46.
3. CABANILLAS F, HAGEMEISTER FB, BODEY GP, FREIREICH EJ. IMVP-16: an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. Blood 1982;60:693-697.
4. CABANILLAS F, HAGEMEISTER FB, McLAUGHLIN P, et al. Results of MIME salvage regimen for recurrent or refractory lymphoma. J Clin Oncol 1987;5:407-412.
5. VELASQUEZ WS, CABANILLAS F, SALVADOR P, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988;71:117-122.
6. VELASQUEZ WS, McLAUGHLIN P, TUCKER S, et al. ESHAP - an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 1994;12:1169-1176.
7. TANOSAKI R, OKAMOTO S, AKATSUKA N. et al. Dose escalation of biweekly cyclophosphamide, doxorubicin, vincristine, and prednisolone using recombinant human granulocyte colony stimulating factor in non-Hodgkin's lymphoma. Cancer 1994;74:1939-1944.
8. SANTORO A, BALZAROTTI M, TONDINI C, et al. Dose-escalation of CHOP in non-Hodgkin's lymphoma. Ann Oncol 1999;10:519-525.
9. GIANNI AM, BREGNI M, SIENA S, et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997;336:1290-1297.
10. VOSE JM, LINK BK, GROSSBARD ML, et al. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 2001;19:389-397.
11. The Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute-sponsored study of classifications of non-Hodgkin's lymphomas. Summary and description of a working formulation for clinical usage. Cancer 1982;49:2112-2135.
12. CARBONE PP, KAPLAN HS, MUSSHOFF K, SMITHERS DW, TUBIANA M. Report of the committee on Hodgkin's disease staging classification. Cancer Res 1971;31:1860-1861.
13. KAPLAN EL, MEIER P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457-481.
14. Cox DR. Regression models and life tables (with discussions). J R Stat Soc (Ser B) 1972;34:187-220.
15. JAFFE ES, HARRIS NL, STEIN H, VARDIMAN JW, eds. World Health Organization Classification Of Tumors, Pathology and Genetics. Tumors Of Haematopoietic And Lymphoid Tissues. Lyon: IARC Press, 2001:109-236.
16. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987-994.
17. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland: WHO, 1979.
18. PHILIP T, GUGLIELMI C, HAGENBEEK A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333:1540-1545.
19. VAN BESIEN K, RODRIGUEZ A, TOMANY S, et al. Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival. Bone Marrow Transplant 2001;27:397-404.
20. RATANATHARATHORN V, UBERTI J, KARANES C, et al. Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma. Blood 1994;84:1050-1055.
21. DANN EJ, DAUGHERTY CK, LARSON RA. Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma. Bone Marrow Transplant 1997;20:369-374.
22. CHILDS R, CLAVE E, CONTENTIN N, et al. Engraftment kinetics after non-myeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood 1999; 94:3234-3241.